When state officials pledged $7.4 million to Organogenesis in 2009, they heralded the grant as a way to reward a promising biotech firm that sought to more than double its local workforce.
But the Canton firm’s growth trajectory was cut in late 2013, when the federal government sliced reimbursement rates for its main skin-graft product. Instead of reaching its target of 500 employees in Massachusetts by the end of 2014 as promised, the company ended up with fewer local workers — about 200 — than it had when it received the grant.
Hey, check out all the engineering jobs. Post your resume today!
